Investors

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Net assets

£1414.9m

Fully diluted NAV per share

210.7p

Life science portfolio value

£677m

Capital pool supporting investment in life science

£737.9m

Portfolio snapshot

  • 9 portfolio companies in innovative areas of life science
  • 800+ employees across Syncona portfolio
  • 9 live clinical trials across the portfolio